Analysts' average 12-month price target for Generate Biomedicines is $24.
Get informed when a big investor buys or sells
+ Follow$15.09
2 analysts in the last 4 months
High: $25 | Low: $22
No recommendations in the last 4 months.
The latest target price for GENB is $24. Investors often review this figure alongside Generate Biomedicines's historical trend and sector peers before judging valuation or financial health.
Generate Biomedicines trades near $15.09 while the consensus target sits at $24 (55.7% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.
After noting GENB's target price ($24), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.